Meeting
2018 ASCO Annual Meeting
Analysis of tumor samples from SOLO2: Concordance of BRCA mutation (BRCAm) detection in tumor vs. blood and frequency of BRCA-specific loss of heterozygosity (LOH) and loss of function somatic mutations.
Authors
Darren R. Hodgson
AstraZeneca, Cambridge, United Kingdom
Darren R. Hodgson , Simon Patrick Dearden , Jessica S Brown , Tsveta Milenkova , Jerry S Lanchbury , Michael Perry , Alexander Gutin , Victor Abkevich , Kirsten Timms , Elizabeth Harrington , J Carl Barrett , Zhongwu Lai , Brian Andrew Dougherty , Eric Pujade-Lauraine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Clinical Trial Registration Number
NCT01874353
Citation
J Clin Oncol 36, 2018 (suppl; abstr 12017)
DOI
10.1200/JCO.2018.36.15_suppl.12017
Abstract #
12017
Poster Bd #
130
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials.
First Author: Kirsten Timms
Poster
2020 ASCO Virtual Scientific Program
Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer.
First Author: Kirsten M Timms
First Author: Emmanouil S. Saloustros
Poster
2023 ASCO Annual Meeting
Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.
First Author: Kim Anna Reiss